Osiris Therapeutics takes 2Q loss as payments fall

Osiris Therapeutics Inc. said Monday it took a loss in the second quarter, but the company received the first two marketing approvals for its stem cell therapy Prochymal.

Visit link:

Osiris Therapeutics takes 2Q loss as payments fall

Related Posts

Comments are closed.